Education
About Us
Working with TipRanks
Follow Us
Privia Health Group (PRVA)
NASDAQ:PRVA
PRVA Analyst Ratings
Strong Buy
17 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRVA Stock 12 Month Forecast
Average Price Target
$29.94
▲(30.97% Upside)
| Highest Price Target$40.00 | Average Price Target$29.94 | Lowest Price Target$23.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
Reiterated
04/17/25
Robert W. Baird
Reiterated
04/15/25
Barclays
Reiterated
04/10/25
Evercore ISI
Reiterated
04/09/25
Needham
Reiterated
03/21/25
J.P. Morgan
Reiterated
03/17/25
Leerink Partners
Reiterated
03/13/25
Stephens
Reiterated
03/05/25
BTIG
Reiterated
03/05/25
Jefferies
Reiterated
03/04/25
Stifel Nicolaus
$26→$30
Buy
31.23%
Upside
Reiterated
03/03/25
Privia Health Group (PRVA) Gets a Buy from Stifel Nicolaus
Canaccord Genuity
$29→$30
Buy
31.23%
Upside
Reiterated
02/28/25
Privia Health price target raised to $30 from $29 at CanaccordPrivia Health price target raised to $30 from $29 at Canaccord
Piper Sandler
$25→$40
Buy
74.98%
Upside
Reiterated
02/28/25
Privia Health Group Inc (PRVA) PT Raised to $40 at Piper SandlerPiper Sandler analyst Sean Wieland raised the price target on Privia Health Group Inc (NASDAQ: PRVA) to $40.00 (from $25.00) while maintaining an Overweight rating.
JMP Securities
$29
Buy
26.86%
Upside
Reiterated
02/28/25
Privia Health Group's Strong Performance and Promising Outlook Justifies Buy RatingWe maintain our Market Outperform rating on Privia Health (PRVA). On Thursday morning, PRVA reported 4Q results, with all key operating and financial metrics topping our projections. Practice Collections increased 4.7% Y/Y to $792.5M, topping our $733.0M estimate and consensus of $720.4M, while GAAP revenue improved 4.6% Y/Y . As a reminder, 2024 Practice Collections were challenged by a $198M headwind associated with renegotiated MA capitation agreements.
Unknown Analyst
Not Ranked
UBS
$27→$31
Buy
35.61%
Upside
Reiterated
02/28/25
Privia Health Group Inc (PRVA) PT Raised to $31 at UBSUBS raised its price target on Privia Health Group Inc (NASDAQ: PRVA) to $31.00 (from $27.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
Reiterated
04/17/25
Robert W. Baird
Reiterated
04/15/25
Barclays
Reiterated
04/10/25
Evercore ISI
Reiterated
04/09/25
Needham
Reiterated
03/21/25
J.P. Morgan
Reiterated
03/17/25
Leerink Partners
Reiterated
03/13/25
Stephens
Reiterated
03/05/25
BTIG
Reiterated
03/05/25
Jefferies
Reiterated
03/04/25
Stifel Nicolaus
$26→$30
Buy
31.23%
Upside
Reiterated
03/03/25
Privia Health Group (PRVA) Gets a Buy from Stifel Nicolaus
Canaccord Genuity
$29→$30
Buy
31.23%
Upside
Reiterated
02/28/25
Privia Health price target raised to $30 from $29 at CanaccordPrivia Health price target raised to $30 from $29 at Canaccord
Piper Sandler
$25→$40
Buy
74.98%
Upside
Reiterated
02/28/25
Privia Health Group Inc (PRVA) PT Raised to $40 at Piper SandlerPiper Sandler analyst Sean Wieland raised the price target on Privia Health Group Inc (NASDAQ: PRVA) to $40.00 (from $25.00) while maintaining an Overweight rating.
JMP Securities
$29
Buy
26.86%
Upside
Reiterated
02/28/25
Privia Health Group's Strong Performance and Promising Outlook Justifies Buy RatingWe maintain our Market Outperform rating on Privia Health (PRVA). On Thursday morning, PRVA reported 4Q results, with all key operating and financial metrics topping our projections. Practice Collections increased 4.7% Y/Y to $792.5M, topping our $733.0M estimate and consensus of $720.4M, while GAAP revenue improved 4.6% Y/Y . As a reminder, 2024 Practice Collections were challenged by a $198M headwind associated with renegotiated MA capitation agreements.
Unknown Analyst
Not Ranked
UBS
$27→$31
Buy
35.61%
Upside
Reiterated
02/28/25
Privia Health Group Inc (PRVA) PT Raised to $31 at UBSUBS raised its price target on Privia Health Group Inc (NASDAQ: PRVA) to $31.00 (from $27.00) while maintaining a Buy rating.
Best Analysts Covering Privia Health Group
Which Analyst Should I Follow If I Want to Buy PRVA and Sell After:
1 Month
xxx
Success Rate
8/21 ratings generated profit
Average Return
-0.56%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.10% of your transactions generating a profit, with an average return of -0.56% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+3.57%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +3.57% per trade.
1 Year
Success Rate
5/8 ratings generated profit
Average Return
+0.94%
reiterated a buy rating 15 days ago
Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +0.94% per trade.
2 Years
xxx
Success Rate
6/8 ratings generated profit
Average Return
+7.09%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +7.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRVA Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
0
0
1
1
1
Buy
15
16
17
22
22
Hold
3
2
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
18
18
23
24
Each month's total comprises the sum of three months' worth of ratings.
PRVA Financial Forecast
PRVA Stock Forecast FAQ
What is PRVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Privia Health Group’s 12-month average price target is 29.94.
What is PRVA’s upside potential, based on the analysts’ average price target?
Privia Health Group has 30.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRVA a Buy, Sell or Hold?
Privia Health Group has a consensus rating of Strong Buy which is based on 17 buy ratings, 1 hold ratings and 0 sell ratings.
What is Privia Health Group’s price target?
The average price target for Privia Health Group is 29.94. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $23.00. The average price target represents 30.97% Increase from the current price of $22.86.
The highest analyst price target is $40.00 ,the lowest forecast is $23.00. The average price target represents 30.97% Increase from the current price of $22.86.
What do analysts say about Privia Health Group?
Privia Health Group’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of PRVA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.